GlaxoSmithKlineThe Impact of Medicines - Annual Review 2002
Reporting Front PageDownloads

Annual Review 2002 home
Chairman and Chief Executive Officer's statement
Patients and product development
R&D productivity
Innovative science
Diseases of the developing world
Our people
Corporate and social responsibility
Product portfolio
The Board
The Corporate Executive Team
Business operating review
Responsibility statement
Corporate governance
Summary financial statement
Summary remuneration report
Shareholder information
Contact details
Product Portfolio
 
Previous
Next
 
Across the Group's portfolio of products, six major therapeutic areas experienced double-digit percentage growth for 2002 including the fast growing franchises of central nervous system (17%), respiratory (16%), anti-virals (12%) and vaccines (16%).

Top 10 pharmaceutical products
SEROXAT/PAXIL £2.1bn/$3.1bn Central Nervous System (CNS) A selective serotonin re-uptake inhibitor for the treatment of depression and anxiety disorders. SERETIDE/ADVAIR £1.6bn/$2.4bn Respiratory A combination of Serevent and Flixotide that offers a long-acting bronchodilator and an anti-inflammatory in a single inhaler. AUGMENTIN £1.2bn/$1.8bn Anti-bacterials An antibiotic for the treatment of most common respiratory tract infections.
SEROXAT/PAXIL £2.1bn/$3.1bn Central Nervous System (CNS) A selective serotonin re-uptake inhibitor for the treatment of depression and anxiety disorders. SERETIDE/ADVAIR £1.6bn/$2.4bn Respiratory A combination of Serevent and Flixotide that offers a long-acting bronchodilator and an anti-inflammatory in a single inhaler. AUGMENTIN £1.2bn/$1.8bn Anti-bacterials An antibiotic for the treatment of most common respiratory tract infections.
WELLBUTRIN £882m/$1.3bn CNS An anti-depressant available in the USA in normal tablet or sustained release tablet formulations. AVANDIA £809m/$1.2bn Metabolic and gastro-intestinal A member of the newest class of oral treatments for type 2 diabetes. IMIGRAN/IMITREX £798m/$1.2bn CNS A 5HT1 receptor agonist for the treatment of severe or frequent migraine and cluster headaches.
WELLBUTRIN £882m/$1.3bn CNS An anti-depressant available in the USA in normal tablet or sustained release tablet formulations. AVANDIA £809m/$1.2bn Metabolic and gastro-intestinal A member of the newest class of oral treatments for type 2 diabetes. IMIGRAN/IMITREX £798m/$1.2bn CNS A 5HT1 receptor agonist for the treatment of severe or frequent migraine and cluster headaches.
FLIXOTIDE/FLOVENT £783m/$1.2bn Respiratory An inhaled steroid for the treatment of inflammation associated with respiratory diseases. ZOFRAN £708m/$1.1bn Oncology and emesis Used to prevent nausea and vomiting associated with chemotherapy and radiation for cancer. COMBIVIR £588m/$882m Anti-virals A combination of Retrovir and Epivir which reduces the
FLIXOTIDE/FLOVENT £783m/$1.2bn Respiratory An inhaled steroid for the treatment of inflammation associated with respiratory diseases. ZOFRAN £708m/$1.1bn Oncology and emesis Used to prevent nausea and vomiting associated with chemotherapy and radiation for cancer. COMBIVIR £588m/$882m Anti-virals A combination of Retrovir and Epivir which reduces the
FLIXONASE/FLONASE £534m/$801m Respiratory An intra-nasal preparation for the treatment of perennial and seasonal rhinitis.
FLIXONASE/FLONASE £534m/$801m Respiratory An intra-nasal preparation for the treatment of perennial and seasonal rhinitis.

Major launches in 2002

PAXIL CR CNS Launched in the USA in April, Paxil CR combines the efficacy of Paxil with a controlled release technology for the treatment of major depressive disorder and panic disorder. AVANDAMET Metabolic and gastro-intestinal Avandamet was launched in the USA in November, combining Avandia, which targets insulin resistance, and metformin, an oral diabetes therapy, in one convenient pill. AUGMENTIN XR Anti-bacterials A new enhanced formulation of Augmentin for adults to treat communityacquired pneumonia, acute bacterial sinusitis and chronic bronchitis.
PAXIL CR CNS Launched in the USA in April, Paxil CR combines the efficacy of Paxil with a controlled release technology for the treatment of major depressive disorder and panic disorder. AVANDAMET Metabolic and gastro-intestinal Avandamet was launched in the USA in November, combining Avandia, which targets insulin resistance, and metformin, an oral diabetes therapy, in one convenient pill. AUGMENTIN XR Anti-bacterials A new enhanced formulation of Augmentin for adults to treat communityacquired pneumonia, acute bacterial sinusitis and chronic bronchitis.

Vaccines
HEPATITIS VACCINES £483m/$725m A range of treatments protecting against hepatitis A (Havrix) and hepatitis B (Engerix-B). The first combined hepatitis A and B vaccine (Twinrix) protects against both diseases in one course of injections. INFANRIX £254m/$381m A range of vaccines for diphtheria, tetanus and whooping cough.
HEPATITIS VACCINES £483m/$725m A range of treatments protecting against hepatitis A (Havrix) and hepatitis B (Engerix-B). The first combined hepatitis A and B vaccine (Twinrix) protects against both diseases in one course of injections. INFANRIX £254m/$381m A range of vaccines for diphtheria, tetanus and whooping cough.

Top 5 consumer healthcare products
AQUAFRESH £344m/$516m One of the world's largest toothpaste and toothbrush brands. LUCOZADE £214m/$321m The glucose energy drink which provides nutrients to complement a healthy lifestyle. NICODERM CQ/ NIQUITIN CQ/NICABATE £193m/$290m Nicotine replacement therapy available as a patch and in lozenge form.
AQUAFRESH £344m/$516m One of the world's largest toothpaste and toothbrush brands. LUCOZADE £214m/$321m The glucose energy drink which provides nutrients to complement a healthy lifestyle. NICODERM CQ/ NIQUITIN CQ/NICABATE £193m/$290m Nicotine replacement therapy available as a patch and in lozenge form.
SENSODYNE £192m/$288m A toothpaste which addresses dental sensitivity and pain. RIBENA £192m/$288m A range of juice drinks rich in vitamin C.
SENSODYNE £192m/$288m A toothpaste which addresses dental sensitivity and pain. RIBENA £192m/$288m A range of juice drinks rich in vitamin C.

 
Previous
Next


Top


Annual Review 2002 Home | Reporting Front Page | Downloads | Main Site
 
Updated March 28, 2003 - © 2005 GlaxoSmithKline - All Rights Reserved
Legal Notices - Privacy Statement